西酞普兰联合阿立哌唑治疗中度至重度抑郁症的疗效及安全性研究

摘要/Abstract

摘要： 目的：探讨西酞普兰联合阿立哌唑治疗中度至重度抑郁症疗效及安全性。方法：选取2018年12月至2019年12月于我院接受治疗的80例患有中重度抑郁症患者，依据随机抽签法分为观察组（40例）与对照组（40例）。观察组予以西酞普兰联合阿立哌唑治疗，对照组予以单纯西酞普兰治疗。对比两组HDRS评分、疗效、不良事件。结果：观察组HDRS评分在从基线到第2周（8.10±1.35）、从基线到第4周（12.59±1.80）、从基线到第6周（15.49±1.74）均明显大于对照组HDRS评分（P<0.05）。两组患者第2周能回应人数对比无明显差异（P>0.05）。观察组早期改善的数量、第4周能回应人数、第6周能回应人数、第6周症状缓解者均明显大于对照组（P<0.05）。两组患者嗜睡、便秘、头晕、腹痛、食欲增加、食欲下降、恶心、头痛、口干、咳嗽、腹泻对比无明显差异（P>0.05）。结论：中度至重度抑郁症患者采用西酞普兰联合阿立哌唑治疗效果良好，安全性高，值得临床推广。

关键词: font-size:medium, ">重度抑郁症；阿立哌唑；谷氨酸；汉密尔顿抑郁评定量表

Abstract: Objective： To investigate the Hamilton Depression Rating Scale (HDRS)， clinical efficacy and safety comparison of citalopram combined with aripiprazole and citalopram alone in the treatment of moderate to severe depression. Methods： A total of 80 patients with moderate to severe depression who were treated in our hospital from December 2018 to December 2019 were selected and divided into an observation group (40 cases) and a control group (40 cases) according to the random lottery method. The observation group was treated with citalopram combined with aripiprazole， and the control group was treated with citalopram alone. The HDRS score， efficacy， and adverse events of the two groups were compared. Results： The HDRS scores of the observation group from baseline to 2 weeks (8.10±1.35)， from baseline to 4 weeks (12.59±1.80)， and from baseline to 6 weeks (15.49±1.74) were significantly higher than those of the control group (P<0.05). There was no significant difference in the number of patients able to respond at the second week between the two groups (P>0.05). The number of early improvement， the number of responders at week 4， the number of responders at week 6， and the number of symptom remission at week 6 in the observation group were significantly higher than those in the control group (P<0.05). There were no significant differences in drowsiness， constipation， dizziness， abdominal pain， increased appetite， decreased appetite， nausea， headache， dry mouth， cough and diarrhea between 2 groups (P>0.05). Conclusion： The combination of citalopram and aripiprazole in patients with moderate to severe depression has a good effect and high safety， and it is worthy of clinical promotion.

Key words: font-size:medium, ">Major depression；Aripiprazole；Glutamate；Hamilton Depression Rating Scale

中图分类号:

白由竹. 西酞普兰联合阿立哌唑治疗中度至重度抑郁症的疗效及安全性研究[J]. 中国药物评价, 2021, 38(5): 441-444.

BAI You-zhu. Efficacy and Safety of Citalopram Combined with Aripiprazole in the Treatment of Moderate to Severe Depression[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2021, 38(5): 441-444.

参考文献

[1]张颖，段冬梅，胡园，等. 抑郁症合并代谢性疾病的共病机制及其治疗药物的研究进展[J]. 现代药物与临床， 2020， 35(4)：807-814.
     [2]李国樑，郑杰蔚，殷霄，等. 1，2-二氯乙烷亚急性暴露对大鼠抑郁样行为及单胺神经递质水平的影响[J]. 中国职业医学， 2019， 46(2)：152-156.
     [3]郭定波，陈暇女，黄俊浩，等. γ-氨基丁酸和谷氨酸参与产后抑郁症的氢质子磁共振波谱研究进展[J]. 中国神经精神疾病杂志， 2020，46（1）：54-57.
     [4]王晓龙，张惠云. 谷氨酸及其受体在抑郁症病机和治疗中的作用研究进展[J]. 医学研究杂志， 2019， 42(9)：13-16.
     [5]陈海莹，蔡亦蕴，胡瑶，等. 阿立哌唑抑制Sirt1/FoxO3信号转导通路改善MK-801诱导精神分裂症小鼠的机制研究[J]. 河北医药， 2019， 41(3)：10-14.
     [6]孙庆芳，王亚平. 阿立哌唑联合度洛西汀治疗抑郁症的临床研究[J]. 现代药物与临床， 2020， 35(4)：712-716.
     [7]付可登，李松华，胡媛媛，等. 重度抑郁症患者自杀意念相关因素及干预现状调查研究[J]. 中国预防医学杂志， 2020， 21(6)：113-116.
     [8]赵锁，蔡国洪，朱媛媛，等. mGluR5参与睡眠剥夺抗抑郁作用的研究进展[J]. 生理科学进展， 2019， 50(1)：41-44.
     [9]彭霞，张兰. 阿立哌唑增效治疗抑郁症研究进展[J]. 医学综述， 2019， 25(17)：3502-3507.
     [10]王科平，邢文静，韩宇扬. 阿立哌唑联合草酸艾司西酞普兰在重度抑郁症治疗中的应用分析[J]. 川北医学院学报， 2020， 35(1)：42-44.
     [11]Zarate JR， C A， Payne， et al. An open-label trial of riluzole in patients with treatment-resistant omajor depression. Am[J]. Psychiatry， 2019， 57(92)：32-41.
     [12]Brennan， BP， Hudson， et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole[J]. Neuropsychopharmacology， 2020， 231(76)：834-846.
     [13]Banasr M， Chowdhury G， Terwilliger R， et al. Glial pathology in an animal model of depression： reversal of stress-induced cellular， metabolic and behavioral deficits by the glutamate-modulating drug riluzole[J]. Mol Psychiatry， 2019， 79(149)：501-511.
     [14]Gourley SL， Espitia JW， Sanacora G， et al. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice[J]. Psychopharmacology， 2019， 46(2)：805-814.
     [15]Zarate JR， C A， Quiroz， et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression[J]. Biol Psychiatry， 2020，36：430-432.